Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

December 2024

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Res Ther. 2024 12;26:197 doi 10.1186/s13075-024-03412-8

Bu X,

Wung P,

Kato K,

Shmagel A,

Deodhar A

Baraliakos et al. assessed the long-term efficacy and safety of upadacitinib in patients with active ankylosing spondylitis who were refractory to biologic therapy. At week 104, the treatment sustained improvements in disease activity and functional outcomes with low rates of radiographic progression and no new safety signals.

Keywords:

September 2024

Enhanced type 1 interferon signature in axial spondyloarthritis patients unresponsive to secukinumab treatment

Arthritis Rheumatol 2024 Epub ahead of print doi: 10.1002/art.42974

Tang M,

Lim M,

Yau E,

Pacheco et al. demonstrated that, compared with axSpA patients who respond to secukinumab, patients who do not respond show increased IL-17A-producing cells and have a more pronounced type 1 IFN signature, indicating a larger inflammatory burden.